Evaluation of Drug-Drug Interaction Potential Between the Oral Antibiotic Zolifl...

연구 요약

Evaluation of Drug-Drug Interaction Potential Between the Oral Antibiotic Zoliflodacin and the CYP3A4 Inhibitor Itraconazole: A Phase 1 Study in Healthy Participants.

Clinical and translational science 학술지에 발표된 이 연구는 Luckey A, Larson KB, Rayad N 외 연구팀이 수행하였습니다.

이 연구는 'Evaluation of Drug-Drug Interaction Potential Between the Oral Antibiotic Zoliflodacin and the CYP3A4 Inhibitor Itraconazole: A Phase 1 Study in Healthy Participants.'에 대한 과학적 분석을 제공합니다.

핵심 내용

Zoliflodacin is a first-in-class oral spiropyrimidinetrione antibiotic being developed for patients with uncomplicated gonorrhea, including those infected with multidrug-resistant strains. Because zoliflodacin is metabolized by cytochrome P450 3A4 (CYP3A4), concomitant administration with a CYP3A inhibitor has the potential to increase zoliflodacin plasma exposure. The aim of this phase 1 drug-drug interaction (DDI) study was to assess the effect of the strong CYP3A4 inhibitor itraconazole on the pharmacokinetics (PK) and safety of a 3 g single oral dose of zoliflodacin. This was an open label, 2-period, 2-treatment, fixed sequence crossover DDI study. Eighteen eligible adult participants were dosed and completed the study. When zoliflodacin was co-administered with itraconazole at steady state, as determined by itraconazole trough plasma concentrations, zoliflodacin exposure increased as measured by peak concentration (Cmax) by 1.03-fold and by area under the plasma-concentration time curve (AUC) from time 0 to last measurable plasma concentration (AUC0-last) and from time 0 extrapolated to infinity (AUC0-∞) by 1.39- and 1.38-fold, respectively. Eight participants (44.4%) had a total of 15 mild treatment-emergent adverse events (TEAEs), with three considered related to treatment. There were no deaths or serious TEAEs and no participant withdrew. No clinically significant abnormal laboratory values, vital signs, or electrocardiogram findings were reported. In conclusion, the Cmax of zoliflodacin was essentially unchanged (1.03-fold higher) when co-administered with a strong CYP3A4 inhibitor, while AUC exposures increased by less than 1.5-fold, which, combined with an acceptable safety profile, indicate a low DDI potential between zoliflodacin and CYP3A4 inhibitors.

일반인을 위한 해석

구체적인 실천 사항은 담당 의사 또는 약사와 상담하시기 바랍니다.

실천 사항

• 현재 복용 중인 약물이나 영양제에 대해 궁금한 점이 있다면 담당 의사 또는 약사와 상담하시기 바랍니다
• 약물이나 영양제의 용법·용량을 임의로 변경하지 마세요
• 이상 반응이 나타나면 즉시 전문가에게 문의하세요

의사/약사의 전문적 판단을 대체하지 않습니다 (PMID: 41757749)

📄 [전문 보기 (Markdown)](fulltext/41757749-evaluation-of-drug-drug-interaction-potential-between-the-or.md)